Evommune publishes corporate deck outlining chronic inflammation drug pipeline, led by EVO756 and EVO301 programs

Evommune, Inc.

EVMN

0.00

Evommune highlighted two Phase 2 inflammation assets, led by oral MRGPRX2 antagonist EVO756 for atopic dermatitis, migraine, and other indications.
EVO756 Phase 2b atopic dermatitis top-line data expected in Q3 2026; Phase 2b migraine trial initiation targeted for mid-2026.
Earlier EVO756 Phase 2 chronic inducible urticaria study showed 30% complete response at week 4; 70% had at least 1-point improvement.
IL-18 blocker EVO301 posted positive Phase 2a proof-of-concept in atopic dermatitis; full dataset slated for a medical meeting.
EVO301 Phase 2b planning underway in atopic dermatitis; Phase 2 planning underway in ulcerative colitis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief on July 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.